Glioblastoma: exosome and microRNA as novel diagnosis biomarkers.
Glioblastoma (GBM) is known as a tumor type, which arises from astrocytes. Several studies indicated that GBM tumor cells are malignant. This is because of the fact that they consist of different cell types, which are reproducing very quickly and are also supported by a large network of blood vessels. The correct identification of various stages of GBM could help to better treat the patients with this disease. Therefore, new biomarkers such as exosomes and microRNAs (miRNAs) may help us to learn more about GBM and they may also lead to a more effective treatment for patients with GBM. Exosomes have emerged as biological vehicles, which can perform various tasks in carcinogenesis pathways such as PI3K/AKT, SOX2, PTEN, ERK, and STAT3. The miRNAs are known as small noncoding RNAs that are involved in several GBM pathogenic events. These molecules have key roles in various biological processes such as angiogenesis, metastasis and tumor growth. In this study, we highlighted various exosomes and miRNAs that could be used for diagnosis and/or prognosis biomarkers in patients with GBM.
Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
L
L
Saadatpour
Faculty of Medicine, Islamic Azad University of Najafabad, Najafabad, Iran.
E
E
Fadaee
Student Research Committee, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
S
S
Fadaei
Department of Clinical Biochemistry, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
R
R
Nassiri Mansour
Hepatitis Research Center and Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran.
M
M
Mohammadi
Department of Neuroscience, School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.
S M
SM
Mousavi
Department of Biosystems, Faculty of Bioscience Engineering, Katholieke Universiteit Leuven, Leuven, Belgium.
M
M
Goodarzi
Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.|Department of Applied Cell Sciences, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
J
J
Verdi
Department of Applied Cell Sciences, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.|Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
H
H
Mirzaei
D000818:Animals; D014408:Biomarkers, Tumor; D055354:Exosomes / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D011379:Prognosis
D014408:Biomarkers, Tumor; D035683:MicroRNAs